Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SKB571
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $37.5 million
Deal Type : Licensing Agreement
Merck & Co. Buys Kelun ADC For $37.5M, Drops Another Asset
Details : Merck has taken up its option on SKB571, a bispecific ADC that Kelun sees primarily as a treatment of solid tumors such as lung cancer and gastrointestinal tumors.
Product Name : SKB571
Product Type : Large molecule
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : SKB571
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $37.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Macromolecule-based Therapeutic
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland’s Merck Sharp & Dohme
Details : The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : $47.0 million
May 16, 2022
Lead Product(s) : Macromolecule-based Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
Reset All
